{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:37:01Z","timestamp":1792787821721,"version":"4.5.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":88,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"NIA","award":["K01AG071843"],"award-info":[{"award-number":["K01AG071843"]}]},{"name":"NIH","award":["R01 MH121424"],"award-info":[{"award-number":["R01 MH121424"]}]},{"name":"University of Washington Behavioral Research Center for HIV","award":["P30 MH123248"],"award-info":[{"award-number":["P30 MH123248"]}],"id":[{"id":"https:\/\/ror.org\/00cvxb145","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-026-13927-x","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T09:36:37Z","timestamp":1783676197000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Heterogeneity of patient preferences for long-acting HIV treatment among people with HIV in Kenya"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8879-6354","authenticated-orcid":false,"given":"Enrique M.","family":"Saldarriaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Hauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacinda","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Kaggiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Maina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naum","family":"Jepkosgei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Mwangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Barthold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kinuthia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"13927_CR1","unstructured":"UNAIDS. UNAIDS country factsheet. Kenya 2023. 2024. https:\/\/www.unaids.org\/en\/regionscountries\/countries\/kenya."},{"key":"13927_CR2","unstructured":"The Urgency of Now: AIDS at a Crossroads \u2014 2024 Global AIDS Update. 2024. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2024-unaids-global-aids-update_en.pdf."},{"key":"13927_CR3","doi-asserted-by":"publisher","first-page":"e25729","DOI":"10.1002\/jia2.25729","volume":"24","author":"H Musyoki","year":"2021","unstructured":"Musyoki H, et al. A decade and beyond: learnings from HIV programming with underserved and marginalized key populations in Kenya. J Int AIDS Soc. 2021;24:e25729.","journal-title":"J Int AIDS Soc"},{"key":"13927_CR4","doi-asserted-by":"publisher","first-page":"e26245","DOI":"10.1002\/jia2.26245","volume":"27","author":"R Banadakoppa Manjappa","year":"2024","unstructured":"Banadakoppa Manjappa R, et al. A sub-national HIV epidemic appraisal in Kenya: a new approach for identifying priority geographies, populations and programmes for optimizing coverage for HIV prevention. J Int AIDS Soc. 2024;27:e26245.","journal-title":"J Int AIDS Soc"},{"key":"13927_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.5897\/JAHR2020.0513","volume":"12","author":"N Gitahi-Kamau","year":"2020","unstructured":"Gitahi-Kamau N, Wahome S, Bukusi EA, Ngure K. Determinants of antiretroviral therapy adherence among older adolescents living with HIV in Kenya during the transition to adult care; An observational study. J AIDS HIV Res Online. 2020;12:24\u201333.","journal-title":"J AIDS HIV Res Online"},{"key":"13927_CR6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1097\/QAI.0000000000001703","volume":"78","author":"BL Genberg","year":"2018","unstructured":"Genberg BL, et al. Point of Diagnosis and Patient Retention in HIV Care in Western Kenya. J Acquir Immune Defic Syndr 1999. 2018;78:383\u20139.","journal-title":"J Acquir Immune Defic Syndr 1999"},{"key":"13927_CR7","doi-asserted-by":"crossref","unstructured":"Onyango MA, et al. School-level barriers of antiretroviral therapy adherence and interventions to overcome them among adolescents living with HIV in Western Kenya: a qualitative study. Open AIDS J. 2021;15.","DOI":"10.2174\/1874613602115010093"},{"key":"13927_CR8","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1080\/09540121.2016.1220478","volume":"29","author":"SC Kalichman","year":"2017","unstructured":"Kalichman SC, Kalichman MO, Cherry C. Forget about forgetting: structural barriers and severe non-adherence to antiretroviral therapy. AIDS Care. 2017;29:418\u201322.","journal-title":"AIDS Care"},{"key":"13927_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.puhe.2017.12.010","volume":"157","author":"N Ammon","year":"2018","unstructured":"Ammon N, Mason S, Corkery JM. Factors impacting antiretroviral therapy adherence among human immunodeficiency virus\u2013positive adolescents in Sub-Saharan Africa: a systematic review. Public Health. 2018;157:20\u201331.","journal-title":"Public Health"},{"key":"13927_CR10","doi-asserted-by":"publisher","first-page":"e1002183","DOI":"10.1371\/journal.pmed.1002183","volume":"13","author":"Z Shubber","year":"2016","unstructured":"Shubber Z, et al. Patient-Reported Barriers to Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis. PLoS Med. 2016;13:e1002183.","journal-title":"PLoS Med"},{"key":"13927_CR11","doi-asserted-by":"publisher","first-page":"e332","DOI":"10.1016\/S2352-3018(23)00051-6","volume":"10","author":"JB Nachega","year":"2023","unstructured":"Nachega JB, et al. Long-acting antiretrovirals and HIV treatment adherence. Lancet HIV. 2023;10:e332\u201342.","journal-title":"Lancet HIV"},{"key":"13927_CR12","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1080\/17425247.2020.1783233","volume":"17","author":"DA Cobb","year":"2020","unstructured":"Cobb DA, Smith NA, Edagwa BJ, McMillan JM. Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research. Expert Opin Drug Deliv. 2020;17:1227\u201338.","journal-title":"Expert Opin Drug Deliv"},{"key":"13927_CR13","doi-asserted-by":"publisher","first-page":"e679","DOI":"10.1016\/S2352-3018(21)00185-5","volume":"8","author":"H Jaeger","year":"2021","unstructured":"Jaeger H, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2\u00a0M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet HIV. 2021;8:e679\u201389.","journal-title":"Lancet HIV"},{"key":"13927_CR14","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1473-3099(24)00289-5","volume":"24","author":"C Kityo","year":"2024","unstructured":"Kityo C, et al. Switch to long-acting cabotegravir and rilpivirine in virologically suppressed adults with HIV in Africa (CARES): week 48 results from a randomised, multicentre, open-label, non-inferiority trial. Lancet Infect Dis. 2024;24:1083\u201392.","journal-title":"Lancet Infect Dis"},{"key":"13927_CR15","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/hiv.13647","volume":"25","author":"M John","year":"2024","unstructured":"John M, et al. Real-world use of long-acting cabotegravir and rilpivirine: 12-month results of the inJectable Antiretroviral therapy feasiBility Study (JABS). HIV Med. 2024;25:935\u201345.","journal-title":"HIV Med"},{"key":"13927_CR16","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1080\/14787210.2022.2081153","volume":"20","author":"E Taki","year":"2022","unstructured":"Taki E, et al. Cabotegravir\/Rilpivirine: the last FDA-approved drug to treat HIV. Expert Rev Anti Infect Ther. 2022;20:1135\u201347.","journal-title":"Expert Rev Anti Infect Ther"},{"key":"13927_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/COH.0000000000000591","volume":"15","author":"ED Weld","year":"2020","unstructured":"Weld ED, Flexner C. Long-acting implants to treat and prevent HIV infection. Curr Opin HIV AIDS. 2020;15:33\u201341.","journal-title":"Curr Opin HIV AIDS"},{"key":"13927_CR18","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","volume":"386","author":"S Segal-Maurer","year":"2022","unstructured":"Segal-Maurer S, et al. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection. N Engl J Med. 2022;386:1793\u2013803.","journal-title":"N Engl J Med"},{"key":"13927_CR19","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(25)00405-2","volume":"405","author":"V Jogiraju","year":"2025","unstructured":"Jogiraju V, et al. Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study. Lancet. 2025;405:1147\u201354.","journal-title":"Lancet"},{"key":"13927_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.33393\/dti.2021.2342","volume":"15","author":"S Losi","year":"2021","unstructured":"Losi S, et al. The role of patient preferences in adherence to treatment in chronic disease: a narrative review. Drug Target Insights. 2021;15:13\u201320.","journal-title":"Drug Target Insights"},{"key":"13927_CR21","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/hec.3297","volume":"25","author":"F Terris-Prestholt","year":"2016","unstructured":"Terris-Prestholt F, Quaife M, Vickerman P. Parameterising User Uptake in Economic Evaluations: The role of discrete choice experiments. Health Econ. 2016;25:116\u201323.","journal-title":"Health Econ"},{"key":"13927_CR22","doi-asserted-by":"publisher","first-page":"e26095","DOI":"10.1002\/jia2.26095","volume":"26","author":"A Grimsrud","year":"2023","unstructured":"Grimsrud A, et al. The importance of the how: the case for differentiated service delivery of long-acting and extended delivery regimens for HIV prevention and treatment. J Int AIDS Soc. 2023;26:e26095.","journal-title":"J Int AIDS Soc"},{"key":"13927_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JFP Bridges","year":"2011","unstructured":"Bridges JFP, et al. Conjoint Analysis Applications in Health\u2014a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14:403\u201313.","journal-title":"Value Health"},{"key":"13927_CR24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2165\/11539650-000000000-00000","volume":"3","author":"D Marshall","year":"2010","unstructured":"Marshall D, et al. Conjoint Analysis Applications in Health - How are Studies being Designed and Reported? An Update on Current Practice in the Published Literature between 2005 and 2008. Patient. 2010;3:249\u201356.","journal-title":"Patient"},{"key":"13927_CR25","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","volume":"19","author":"AB Hauber","year":"2016","unstructured":"Hauber AB, et al. Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2016;19:300\u201315.","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"13927_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12981-022-00435-6","volume":"19","author":"AT Brah","year":"2022","unstructured":"Brah AT, et al. The systematic development of attributes and levels for a discrete choice experiment of HIV patient preferences for long-acting antiretroviral therapies in the United States. AIDS Res Ther. 2022;19:13.","journal-title":"AIDS Res Ther"},{"key":"13927_CR27","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40271-022-00581-z","volume":"15","author":"D Barthold","year":"2022","unstructured":"Barthold D, Brah AT, Graham SM, Simoni JM, Hauber B. Improvements to Survey Design from Pilot Testing a Discrete-Choice Experiment of the Preferences of Persons Living with HIV for Long-Acting Antiretroviral Therapies. Patient. 2022;15:513\u201320.","journal-title":"Patient"},{"key":"13927_CR28","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1089\/apc.2018.0198","volume":"33","author":"JM Simoni","year":"2019","unstructured":"Simoni JM, et al. Long-Acting Injectable Antiretroviral Treatment Acceptability and Preferences: A Qualitative Study Among US Providers, Adults Living with HIV, and Parents of Youth Living with HIV. AIDS Patient Care STDs. 2019;33:104\u201311.","journal-title":"AIDS Patient Care STDs"},{"key":"13927_CR29","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1007\/s10461-019-02701-7","volume":"24","author":"JM Simoni","year":"2020","unstructured":"Simoni JM, et al. A Conjoint Analysis of the Acceptability of Targeted Long-Acting Injectable Antiretroviral Therapy Among Persons Living with HIV in the U.S. AIDS Behav. 2020;24:1226\u201336.","journal-title":"AIDS Behav"},{"key":"13927_CR30","doi-asserted-by":"publisher","first-page":"e26099","DOI":"10.1002\/jia2.26099","volume":"26","author":"SM Graham","year":"2023","unstructured":"Graham SM, et al. U.S. patient preferences for long-acting HIV treatment: a discrete choice experiment. J Int AIDS Soc. 2023;26:e26099.","journal-title":"J Int AIDS Soc"},{"key":"13927_CR31","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12879-025-10546-w","volume":"25","author":"EM Saldarriaga","year":"2025","unstructured":"Saldarriaga EM, et al. Patient preferences for long-acting HIV treatment: a preference heterogeneity assessment. BMC Infect Dis. 2025;25:237.","journal-title":"BMC Infect Dis"},{"key":"13927_CR32","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1186\/s12879-024-09309-w","volume":"24","author":"A Kaggiah","year":"2024","unstructured":"Kaggiah A, et al. Key informant views on potential acceptability and feasibility of long-acting antiretroviral treatment for HIV in Kenya. BMC Infect Dis. 2024;24:415.","journal-title":"BMC Infect Dis"},{"key":"13927_CR33","doi-asserted-by":"publisher","unstructured":"Maina CN, et al. Adaptation and pilot testing of a discrete choice experiment and survey on patient preferences for long-acting antiretroviral therapies for HIV in Kenya. AIDS Care. 2025;1\u201315. https:\/\/doi.org\/10.1080\/09540121.2025.2587906.","DOI":"10.1080\/09540121.2025.2587906"},{"key":"13927_CR34","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1186\/s12879-026-12804-x","volume":"26","author":"J Tran","year":"2026","unstructured":"Tran J, et al. Patient preferences for long-acting antiretroviral treatment among people with HIV in Kenya: a discrete choice experiment. BMC Infect Dis. 2026;26:570.","journal-title":"BMC Infect Dis"},{"key":"13927_CR35","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s40271-015-0118-z","volume":"8","author":"EW de Bekker-Grob","year":"2015","unstructured":"de Bekker-Grob EW, Donkers B, Jonker MF, Stolk EA. Sample Size Requirements for Discrete-Choice Experiments in Healthcare: a Practical Guide. Patient - Patient-Centered Outcomes Res. 2015;8:373\u201384.","journal-title":"Patient - Patient-Centered Outcomes Res"},{"key":"13927_CR36","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, et al. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42:377\u201381.","journal-title":"J Biomed Inf"},{"key":"13927_CR37","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inf. 2019;95:103208.","journal-title":"J Biomed Inf"},{"key":"13927_CR38","unstructured":"SurveyEngine GmbH. SurveyEngine [Internet]. Berlin: SurveyEngine GmbH; 2021"},{"key":"13927_CR39","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s11121-011-0201-1","volume":"14","author":"ST Lanza","year":"2013","unstructured":"Lanza ST, Rhoades BL. Latent Class Analysis: An Alternative Perspective on Subgroup Analysis in Prevention and Treatment. Prev Sci Off J Soc Prev Res. 2013;14:157\u201368.","journal-title":"Prev Sci Off J Soc Prev Res"},{"key":"13927_CR40","first-page":"584","volume":"28","author":"R Andersen","year":"2003","unstructured":"Andersen R, Hagenaars JA, McCutcheon AL. Applied Latent Class Analysis. Can J Sociol Cah Can Sociol. 2003;28:584.","journal-title":"Can J Sociol Cah Can Sociol"},{"key":"13927_CR41","doi-asserted-by":"publisher","first-page":"S351","DOI":"10.1016\/j.jval.2023.03.2387","volume":"26","author":"J Tran","year":"2023","unstructured":"Tran J, et al. PCR208 Patient Preferences for Long-Acting Antiretroviral Therapy Among Patients Living with HIV in Kenya: Results from a Pilot Discrete Choice Experiment. Value Health. 2023;26:S351.","journal-title":"Value Health"},{"key":"13927_CR42","volume-title":"Stata Statistical Software: Release 14","author":"StataCorp","year":"2015","unstructured":"StataCorp. Stata Statistical Software: Release 14. TX: StataCorp LP, College Station; 2015."},{"key":"13927_CR43","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.jval.2022.01.012","volume":"25","author":"C Vass","year":"2022","unstructured":"Vass C, et al. Accounting for Preference Heterogeneity in Discrete-Choice Experiments: An ISPOR Special Interest Group Report. Value Health. 2022;25:685\u201394.","journal-title":"Value Health"},{"key":"13927_CR44","doi-asserted-by":"publisher","first-page":"232595822110005","DOI":"10.1177\/23259582211000517","volume":"20","author":"JM Simoni","year":"2021","unstructured":"Simoni JM, et al. Lighten This Burden of Ours: Acceptability and Preferences Regarding Injectable Antiretroviral Treatment Among Adults and Youth Living With HIV in Coastal Kenya. J Int Assoc Provid AIDS Care. 2021;20:23259582211000517.","journal-title":"J Int Assoc Provid AIDS Care"},{"key":"13927_CR45","doi-asserted-by":"publisher","first-page":"e0234666","DOI":"10.1371\/journal.pone.0234666","volume":"15","author":"D Kerrigan","year":"2020","unstructured":"Kerrigan D, et al. A dream come true: Perspectives on long-acting injectable antiretroviral therapy among female sex workers living with HIV from the Dominican Republic and Tanzania. PLoS ONE. 2020;15:e0234666.","journal-title":"PLoS ONE"},{"key":"13927_CR46","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s10461-022-03949-2","volume":"27","author":"E Toska","year":"2023","unstructured":"Toska E, et al. Factors Associated with Preferences for Long-Acting Injectable Antiretroviral Therapy Among Adolescents and Young People Living with HIV in South Africa. AIDS Behav. 2023;27:2163\u201375.","journal-title":"AIDS Behav"},{"key":"13927_CR47","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1186\/s12879-025-10871-0","volume":"25","author":"P Gashema","year":"2025","unstructured":"Gashema P, et al. Bridging the gap: identifying barriers and strategies for widespread implementation of long-acting injectable antiretroviral therapy in Sub-Saharan Africa: a scoping review. BMC Infect Dis. 2025;25:476.","journal-title":"BMC Infect Dis"},{"key":"13927_CR48","doi-asserted-by":"publisher","first-page":"S541","DOI":"10.1093\/cid\/ciac716","volume":"75","author":"SE Cooper","year":"2022","unstructured":"Cooper SE, Rosenblatt J, Gulick RM. Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of Human Immunodeficiency Virus (HIV) in High-Income Countries. Clin Infect Dis Off Publ Infect Dis Soc Am. 2022;75:S541\u20138.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"13927_CR49","doi-asserted-by":"publisher","first-page":"e16904","DOI":"10.2196\/16904","volume":"22","author":"CT Rael","year":"2020","unstructured":"Rael CT, et al. Understanding the Acceptability of Subdermal Implants as a Possible New HIV Prevention Method: Multi-Stage Mixed Methods Study. J Med Internet Res. 2020;22:e16904.","journal-title":"J Med Internet Res"},{"key":"13927_CR50","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1186\/s12879-024-09748-5","volume":"24","author":"H Zakumumpa","year":"2024","unstructured":"Zakumumpa H, Alinaitwe A, Kyomuhendo M, Nakazibwe B. Long-acting injectable antiretroviral treatment: experiences of people with HIV and their healthcare providers in Uganda. BMC Infect Dis. 2024;24:876.","journal-title":"BMC Infect Dis"},{"key":"13927_CR51","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1007\/s10461-024-04315-0","volume":"28","author":"XA Erguera","year":"2024","unstructured":"Erguera XA, et al. Acceptability of Long-Acting Injectable Antiretroviral Therapy Among People with HIV Receiving Care at Three Ryan White Funded Clinics in the United States. AIDS Behav. 2024;28:2226\u201338.","journal-title":"AIDS Behav"},{"key":"13927_CR52","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1080\/09540121.2020.1764906","volume":"33","author":"D Dandachi","year":"2021","unstructured":"Dandachi D, Dang BN, Lucari B, Swindells S, Giordano TP. Acceptability and preferences for long-acting antiretroviral formulations among people with HIV infection. AIDS Care. 2021;33:801\u20139.","journal-title":"AIDS Care"},{"key":"13927_CR53","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3390\/jpm12030334","volume":"12","author":"H Gelhorn","year":"2022","unstructured":"Gelhorn H, et al. Patient and Physician Preferences for Regimen Attributes for the Treatment of HIV in the United States and Canada. J Pers Med. 2022;12:334.","journal-title":"J Pers Med"},{"key":"13927_CR54","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/QAI.0000000000002337","volume":"84","author":"MM Philbin","year":"2020","unstructured":"Philbin MM, et al. Multisite Study of Women Living With HIV\u2019s Perceived Barriers to, and Interest in, Long-Acting Injectable Antiretroviral Therapy. J Acquir Immune Defic Syndr 1999. 2020;84:263\u201370.","journal-title":"J Acquir Immune Defic Syndr 1999"},{"key":"13927_CR55","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1089\/apc.2023.0017","volume":"37","author":"CE Kennedy","year":"2023","unstructured":"Kennedy CE, et al. High Acceptability and Perceived Feasibility of Long-Acting Injectable Antiretroviral Treatment Among People Living with HIV Who Are Viremic and Health Workers in Uganda. AIDS Patient Care STDs. 2023;37:316\u201322.","journal-title":"AIDS Patient Care STDs"},{"key":"13927_CR56","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1186\/s12889-019-7276-1","volume":"19","author":"C-Y Cheng","year":"2019","unstructured":"Cheng C-Y, et al. Determinants of heterosexual men\u2019s demand for long-acting injectable pre-exposure prophylaxis (PrEP) for HIV in urban South Africa. BMC Public Health. 2019;19:996.","journal-title":"BMC Public Health"},{"key":"13927_CR57","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12879-024-10414-z","volume":"25","author":"V Ogello","year":"2025","unstructured":"Ogello V, et al. Preferences for and acceptability of long-acting HIV prevention products among pregnant and lactating women accessing health services in Kenya: a mixed method cross-sectional analysis. BMC Infect Dis. 2025;25:37.","journal-title":"BMC Infect Dis"},{"key":"13927_CR58","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1186\/1472-6963-14-469","volume":"14","author":"\u00c1 Lubl\u00f3y","year":"2014","unstructured":"Lubl\u00f3y \u00c1. Factors affecting the uptake of new medicines: a systematic literature review. BMC Health Serv Res. 2014;14:469.","journal-title":"BMC Health Serv Res"},{"key":"13927_CR59","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13561-024-00576-6","volume":"14","author":"GJ Topan","year":"2024","unstructured":"Topan GJ, Thiombiano N, Sarambe I. Determinants of households\u2019 willingness to pay for health insurance in Burkina Faso. Health Econ Rev. 2024;14:93.","journal-title":"Health Econ Rev"},{"key":"13927_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1475-9276-9-1","volume":"9","author":"BS Uzochukwu","year":"2010","unstructured":"Uzochukwu BS, Onwujekwe OE, Uguru NP, Ughasoro MD, Ezeoke OP. Willingness to pay for rapid diagnostic tests for the diagnosis and treatment of malaria in southeast Nigeria: ex post and ex ante. Int J Equity Health. 2010;9:1.","journal-title":"Int J Equity Health"},{"key":"13927_CR61","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/0277-9536(96)00015-9","volume":"1982 43","author":"M Weaver","year":"1996","unstructured":"Weaver M, et al. Willingness to pay for child survival: results of a national survey in Central African Republic. Soc Sci Med. 1996;1982 43:985\u201398.","journal-title":"Soc Sci Med"},{"key":"13927_CR62","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/S2214-109X(23)00510-7","volume":"12","author":"E Odipo","year":"2023","unstructured":"Odipo E, et al. The path to universal health coverage in five African and Asian countries: examining the association between insurance status and health-care use. Lancet Glob Health. 2023;12:e123\u201333.","journal-title":"Lancet Glob Health"},{"key":"13927_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10705511.2014.935265","volume":"22","author":"BC Bray","year":"2015","unstructured":"Bray BC, Lanza ST, Tan X. Eliminating Bias in Classify-Analyze Approaches for Latent Class Analysis. Struct Equ Model. 2015;22:1\u201311.","journal-title":"Struct Equ Model"},{"key":"13927_CR64","doi-asserted-by":"publisher","first-page":"e428","DOI":"10.1016\/S2352-3018(23)00134-0","volume":"10","author":"C Norcross","year":"2023","unstructured":"Norcross C, et al. Long-acting antiretrovirals: research and implementation considerations in Africa. Lancet HIV. 2023;10:e428\u20139.","journal-title":"Lancet HIV"},{"key":"13927_CR65","doi-asserted-by":"publisher","first-page":"e711","DOI":"10.1016\/S2352-3018(24)00173-5","volume":"11","author":"WDF Venter","year":"2024","unstructured":"Venter WDF, et al. The long wait for long-acting HIV prevention and treatment formulations. Lancet HIV. 2024;11:e711\u20136.","journal-title":"Lancet HIV"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13927-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13927-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13927-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:05:43Z","timestamp":1791245143000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13927-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13927"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13927-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]},"assertion":[{"value":"17 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The University of Washington (UW, STUDY00013593) and Kenyatta National Hospital-University of Nairobi Ethics and Research committee (P458\/06\/2021) reviewed and approved the study protocol and informed consent documents. All participants provided written informed consent before taking part in the study. This study was conducted in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided electronic informed consent.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BH is an employee of Pfizer, but Pfizer had no input or influence on the study. SMG has received support from Cepheid for her research. The other authors declare that they have no conflicts of interest directly relevant to the content of this article.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1775"}}